{"id":17125,"date":"2026-03-18T12:47:01","date_gmt":"2026-03-18T12:47:01","guid":{"rendered":"http:\/\/TheNextWeb=6412d8a19f50fc50260463817b74e44f"},"modified":"2026-03-18T12:47:01","modified_gmt":"2026-03-18T12:47:01","slug":"german-biotech-kupando-raises-e10m-more-to-take-its-innate-immunity-drug-into-the-clinic","status":"publish","type":"post","link":"https:\/\/www.londonchiropracter.com\/?p=17125","title":{"rendered":"German biotech Kupando raises \u20ac10M more to take its innate immunity drug into the clinic"},"content":{"rendered":"<p> <img decoding=\"async\" loading=\"lazy\" src=\"https:\/\/cdn0.tnwcdn.com\/wp-content\/blogs.dir\/1\/files\/2026\/03\/Kupando-raises-E10M.png\" width=\"1042\" height=\"586\"><\/p>\n<p>An extension to the company\u2019s Series A brings total funding to \u20ac23 million and clears the path for the first human trial of KUP101, a dual TLR agonist targeting solid tumours and drug-resistant infections. Most immunotherapy research in oncology has concentrated on the adaptive immune system, the learned, antibody-generating machinery that checkpoint inhibitors like pembrolizumab [&hellip;]<\/p>\n<p><a href=\"https:\/\/thenextweb.com\/news\/kupando-series-a-kup101-phase-1b-innate-immunity?utm_source=social&#038;utm_medium=feed&#038;utm_campaign=profeed\">This story continues<\/a> at The Next Web <a href=\"https:\/\/thenextweb.com\/news\/kupando-series-a-kup101-phase-1b-innate-immunity\">Source<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>An extension to the company\u2019s Series A brings total funding to \u20ac23 million and clears the path for the first human trial of KUP101, a dual TLR agonist targeting solid tumours and&#8230;<\/p>\n","protected":false},"author":1,"featured_media":17126,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":[],"categories":[1],"tags":[],"_links":{"self":[{"href":"https:\/\/www.londonchiropracter.com\/index.php?rest_route=\/wp\/v2\/posts\/17125"}],"collection":[{"href":"https:\/\/www.londonchiropracter.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.londonchiropracter.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.londonchiropracter.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.londonchiropracter.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=17125"}],"version-history":[{"count":0,"href":"https:\/\/www.londonchiropracter.com\/index.php?rest_route=\/wp\/v2\/posts\/17125\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.londonchiropracter.com\/index.php?rest_route=\/wp\/v2\/media\/17126"}],"wp:attachment":[{"href":"https:\/\/www.londonchiropracter.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=17125"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.londonchiropracter.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=17125"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.londonchiropracter.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=17125"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}